Details
Janumet Indications
For the treatment of adult patients with diabetes mellitus type II.
Contraindications
Known hypersensitivity to sytahliptynu phosphate, metformin hydrochloride or to any other component of the drug.
Diabetic ketoacidosis, diabetic prekomy.
Renal failure moderate or severe (creatinine clearance <60 ml / min).
Acute conditions that may affect renal function: dehydration, severe infection, shock, intravascular administration of iodine-containing contrast agents.
Acute or chronic disease which may cause tissue hypoxia such as cardiac or pulmonary failure, recent myocardial infarction, shock.
Abnormal liver function.
Acute alcohol intoxication, alcoholism.
The period of lactation.
Diabetes Type I
Dosage & Administration
Janumet usually applied 2 times a day while eating, gradually increasing the dose to minimize potential adverse effects on the gastrointestinal tract that are characteristic of metformin.
Janumet dosage should be individualized, based on current therapy, efficacy and tolerability, but not exceeding the maximum recommended daily dose sytahliptynu - 100 mg.
Available dosage:
Sytahliptynu 50 mg / 500 mg metformin hydrochloride;
Sytahliptynu 50 mg / 850 mg metformin hydrochloride;
Sytahliptynu 50 mg / 1000 mg metformin hydrochloride.
